Adhesive Pili in UTI pathogenesis and drug development

Pathogens

Volumn 5, Issue 1, 2016, Pages

  Spaulding, Caitlin N ^a   Hultgren, Scott J ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Antibiotic resistance; CAUTI; Chaperone usher pathway (CUP) pili; Enterococcus; Pili; RUTI; UPEC; UTI; Vaccine

Indexed keywords

CHAPERONE; CHEMOKINE RECEPTOR CXCR1; CXCL1 CHEMOKINE; GRANULOCYTE COLONY STIMULATING FACTOR; IMMUNOGLOBULIN G ANTIBODY; INTERLEUKIN 1ALPHA; INTERLEUKIN 6;

BACTERIAL COLONIZATION; BACTERIUM PILUS; BACTERIURIA; DISEASE COURSE; EDEMA; ENTEROCOCCUS FAECALIS; GENE EXPRESSION; HOST PATHOGEN INTERACTION; HUMAN; IMMUNE RESPONSE; INTERSTITIAL CYSTITIS; MOLECULAR INTERACTION; NONHUMAN; PATHOPHYSIOLOGY; PROTEIN EXPRESSION; PYELONEPHRITIS; RESPIRATORY TRACT INFECTION; REVIEW; UROPATHOGENIC ESCHERICHIA COLI;

EID: 85026821650     PISSN: None     EISSN: 20760817     Source Type: Journal    
DOI: 10.3390/pathogens5010030     Document Type: Review

References (135)

1. Nicolle, L.E. Catheter-related urinary tract infection. Drugs Aging 2005, 22, 627-639. [CrossRef] [PubMed]
2. Stamm, W.E.; Norrby, S.R. Urinary tract infections: disease panorama and challenges. J. Infect. Dis. 2001, 183, 1-4. [CrossRef] [PubMed]
3. Harding, G.K.; Ronald, A.R. The management of urinary tract infections: what we have learned in the past decade. Int. J. Antimicrob. Agents 1994, 4, 83-88. [CrossRef]
4. Foxman, B. The epidemiology of urinary tract infection. Nat. Rev. Urol. 2010, 7, 653-660. [CrossRef] [PubMed]
5. Foxman, B. Urinary tract infection syndromes: Occurrence, recurrence, bacteriology, risk factors, and disease burden. Infect. Dis. Clin. N. Am. 2014, 28, 1-13. [CrossRef] [PubMed]
6. Hooton, T.M. Uncomplicated urinary tract infection. N. Engl. J. Med. 2012, 366, 1028-1037. [CrossRef] [PubMed]
7. Lichtenberger, P.; Hooton, T.M. Complicated urinary tract infections. Curr. Infect. Dis. Rep. 2008, 10, 499-504. [CrossRef] [PubMed]
8. Levison, M.E.; Kaye, D. Treatment of complicated urinary tract infections with an emphasis on drug-resistant gram-negative uropathogens. Curr. Infect. Dis. Rep. 2013, 15, 109-115. [CrossRef] [PubMed]
9. Lo, E.; Nicolle, L.E.; Coffin, S.E.; Gould, C.; Maragakis, L.L.; Meddings, J.; Pegues, D.A.; Pettis, A.M.; Saint, S.; Yokoe, D.S. Strategies to prevent catheter-associated urinary tract infections in acute care hospitals: 2014 update. Infect. Control Hosp. Epidemiol. 2014, 35, 32-47. [CrossRef]
10. Foxman, B.; Brown, P. Epidemiology of urinary tract infections: Transmission and risk factors, incidence, and costs. Infect. Dis. Clin. N. Am. 2003, 17, 227-241. [CrossRef]
11. Foxman, B. Epidemiology of urinary tract infections: Incidence, morbidity, and economic costs. Am. J. Med. 2002, 113, 5S-13S. [CrossRef]
12. Ikaheimo, R.; Siitonen, A.; Heiskanen, T.; Karkkainen, U.; Kuosmanen, P.; Lipponen, P.; Makela, P.H. Recurrence of urinary tract infection in a primary care setting: Analysis of a 1-year follow-up of 179 women. Clin. Infect. Dis. 1996, 22, 91-99. [CrossRef] [PubMed]
13. Al-Badr, A.; Al-Shaikh, G. Recurrent Urinary Tract Infections Management in Women: A review. Sultan Qaboos Univ. Med. J. 2013, 13, 359-367. [CrossRef] [PubMed]
14. Griebling, T.L. Urinary tract infection in women. Urologic Diseases in Amerca; Litwin, M.S., Saigal, C.S., Eds.; U.S. Government Printing Office: Washington, DC, USA, 2007; pp. 587-620.
15. Flores-Mireles, A.L.; Walker, J.N.; Caparon, M.; Hultgren, S.J. Urinary tract infections: epidemiology, mechanims of infection and treatment options. Nat. Rev. Microbiol. 2015, 13, 269-284. [CrossRef] [PubMed]
16. Chen, S.L.; Wu, M.; Henderson, J.P.; Hooton, T.M.; Hibbing, M.E.; Hultgren, S.J.; Gordon, J.I. Genomic diversity and fitness of E. coli strains recovered from the intestinal and urinary tracts of women with recurrent urinary tract infection. Sci. Transl. Med. 2013. [CrossRef] [PubMed]
17. Moreno, E.; Andreu, A.; Pigrau, C.; Kuskowski, M.A.; Johnson, J.R.; Prats, G. Relationship between Escherichia coli strains causing acute cystitis in women and the fecal E. coli population of the host. J. Clin. Microbiol. 2008, 46, 2529-2534. [CrossRef] [PubMed]
18. Scholes, D.; Hooton, T.M.; Roberts, P.L.; Stapleton, A.E.; Gupta, K.; Stamm, W.E. Risk factors for recurrent urinary tract infection in young women. J. Infect. Dis. 2000, 182, 1177-1182. [CrossRef] [PubMed]
19. Song, J.; Li, B.; Grady, R.; Stapleton, A.; Abraham, S. TLR4-mediated expulsion of bacteria from infected bladder epithelial cells. Proc. Natl. Acad. Soc. USA 2009, 106, 14966-14971. [CrossRef] [PubMed]
20. Busch, A.; Waksman, G. Chaperone-usher pathways: Diversity and pilus assembly mechanism. Philos. Trans. R. Soc. Lond. B Biol. Sci. 2012, 367, 1112-1122. [CrossRef] [PubMed]
21. Holmgren, A.; Brändén, C. Crystal structure of chaperone protein PapD reveals an immunoglobulin fold. Nature 1989, 342, 248-251. [CrossRef] [PubMed]
22. Slonim, L.N.; Pinkner, J.S.; Branden, C.I.; Hultgren, S.J. Interactive surface in the PapD chaperone cleft is conserved in pilus chaperone superfamily and essential in subunit recognition and assembly. EMBO 1992, 11, 4747-4756.
23. Sauer, F.G.; Futterer, K.; Pinkner, J.S.; Dodson, K.W.; Hultgren, S.J.; Waksman, G. Structural basis of chaperone function and pilus biogenesis. Science 1999, 285, 1058-1061. [CrossRef] [PubMed]
24. Barnhart, M.M.; Pinkner, J.S.; Soto, G.E.; Sauer, F.G.; Langermann, S.; Waksman, G.; Frieden, C.; Hultgren, S.J. PapD-like chaperones provide the missing information for folding of pilin proteins. Proc. Natl. Acad. Soc. USA 2000, 97, 7709-7714. [CrossRef] [PubMed]
25. Geibel, S.; Procko, E.; Hultgren, S.J.; Baker, D.; Waksman, G. Structural and energetic basis of folded-protein transport by the FimD usher. Nature 2013, 496, 243-246. [CrossRef] [PubMed]
26. Phan, G.; Remaut, H.; Wang, T.; Allen, W.J.; Pirker, K.F.; Lebedev, A.; Henderson, N.S.; Geibel, S.; Volkan, E.; Yan, J. et al. Crystal structure of the FimD usher bound to its cognate FimC-FimH substrate. Nature 2011, 474, 49-53. [CrossRef] [PubMed]
27. Remaut, H.; Tang, C.; Henderson, N.S.; Pinkner, J.S.; Wang, T.; Hultgren, S.J.; Thanassi, D.G.; Waksman, G.; Li, H. Fiber formation across the bacterial outer membrane by the chaperone/usher pathway. Cell 2008, 133, 640-652. [CrossRef] [PubMed]
28. Thanassi, D.G.; Stathopoulos, C.; Dodson, K.; Geiger, D.; Hultgren, S.J. Bacterial outer membrane ushers contain distinct targeting and assembly domains for pilus biogenesis. Bacteriology 2002, 184, 6260-6269. [CrossRef]
29. Nishiyama, M.; Vetsch, M.; Puorger, C.; Jelesarov, I.; Glockshuber, R. Identification and characterization of the chaperone-subunit complex-binding domain from the type 1 pilus assembly platform FimD. Mol. Biol. 2003, 330, 513-525. [CrossRef]
30. Volkan, E.; Kalas, V.; Pinkner, J.S.; Dodson, K.W.; Henderson, N.S.; Pham, T.; Waksman, G.; Delcour, A.H.; Thanassi, D.G.; Hultgren, S.J. Molecular basis of usher pore gating in Escherichia coli pilus biogenesis. Proc. Natl. Acad. Soc. USA 2013, 110, 20741-20746. [CrossRef] [PubMed]
31. Sauer, F.G.; Pinkner, J.S.; Waksman, G.; Hultgren, S.J. Chaperone priming of pilus subunits facilitates a topological transition that drives fiber formation. Cell 2002, 111, 543-551. [CrossRef]
32. Barnhart, M.M.; Sauer, F.G.; Pinkner, J.S.; Hultgren, S.J. Chaperone-subunit-usher interactions required for donor strand exchange during bacterial pilus assembly. Bacteriology 2003, 1985, 2723-2730. [CrossRef]
33. Remaut, H.; Rose, R.J.; Hannan, T.J.; Hultgren, S.J.; Radford, S.E.; Ashcroft, A.E.; Waksman, G. Donor-strand exchange in chaperone-assisted pilus assembly proceeds through a concerted beta strand displacement mechanism. Mol. Cell 2006, 22, 831-842. [CrossRef] [PubMed]
34. Wu, X.R.; Sun, T.T.; Medina, J.J. In vitro binding of type 1-fimbriated Escherichia coli to uroplakins Ia and Ib: Relation to urinary tract infections. Proc. Natl. Acad. Soc. USA 1996, 93, 9630-9635. [CrossRef]
35. Sun, T.T.; Zhao, H.; Provet, J.; Aebi, U.; Wu, X.R. Formation of asymmetric unit membrane during urothelial differentiation. Mol. Biol. Rep. 1996, 23, 3-11. [CrossRef] [PubMed]
36. Zhou, G.; Mo, W.J.; Sebbel, P.; Min, G.; Neubert, T.A.; Glockshuber, R.; Wu, X.R.; Sun, T.T.; Kong, X.P. Uroplakin Ia is the urothelial receptor for uropathogenic Escherichia coli: Evidence from in vitro FimH binding. J. Cell Sci. 2001, 114, 4095-4103. [PubMed]
37. Hung, C.S.; Bouckaert, J.; Hung, D.; Pinkner, J.; Widberg, C.; De Fusco, A.; Auguste, C.G.; Strouse, B.; Langerman, S.; Waksman, G. et al. Structural basis of tropism of Escherichia coli to the bladder during urinary tract infection. Mol. Microbiol. 2002, 44, 903-915. [CrossRef] [PubMed]
38. Eto, D.S.; Jones, T.A.; Sundsbak, J.L.; Mulvey, M.A. Integrin-mediated host cell invasion by type 1-piliated uropathogenic Escherichia coli. PLoS Pathog. 2007, 3, e100. [CrossRef] [PubMed]
39. Mulvey, M.A.; Schilling, J.D.; Martinez, J.J.; Hultgren, S.J. Bad bugs and beleagured bladders: Interplay between uropathogenic Escherichia coli and innate host defenses. Proc. Natl. Acad. Soc. USA 2000, 97, 8829-8835. [CrossRef]
40. Mulvey, M.A.; Lopez-Boado, Y.S.; Wilson, C.L.; Roth, R.; Parks, W.C.; Heuser, J.; Hultgren, S.J. Induction and Evasion of Host Defenses by Type 1-Piliated Uropathogenic Escherichia coli. Science 1998, 282, 1494-1497. [CrossRef] [PubMed]
41. Martinez, J.J.; Mulvey, M.A.; Schilling, J.D.; Pinkner, J.S.; Hultgren, S.J. Type 1 pilus-mediated bacterial invasion of bladder epithelial cells. EMBO 2000, 19, 2803-2812. [CrossRef] [PubMed]
42. Martinez, J.J.; Hultgren, S.J. Requirment of Rho-family GTPases in the invasion of Type-1 piliated uropathogenic Escherichia coli. Cell. Microbiol. 2002, 4, 19-28. [CrossRef] [PubMed]
43. Anderson, G.G.; Palermo, J.J.; Schilling, J.D.; Roth, R.; Heuser, J.; Hultgren, S.J. Intracellular bacterial biofilm-like pods in urinary tract infections. Science 2003, 301, 105-107. [CrossRef] [PubMed]
44. Justice, S.S.; Hung, C.; Theriot, J.A.; Fletcher, D.A.; Anderson, G.G.; Footer, M.J.; Hultgren, S.J. Differentiation and developmental pathways of uropathogenic Escherichia coli in urinary tract pathogenesis. Proc. Natl. Acad. Soc. USA 2004, 101, 1333-1338. [CrossRef] [PubMed]
45. Hung, C.S.; Dodson, K.W.; Hultgren, S.J. A murine model of urinary tract infection. Nat. Protoc. 2009, 4, 1230-1243. [CrossRef] [PubMed]
46. Wright, K.J.; Seed, P.C.; Hultgren, S.J. Development of intracellular bacterial communities of uropathogenic Escherichia coli depends on type 1 pili. Cell. Microbiol. 2007, 9, 2230-2241. [CrossRef] [PubMed]
47. Mulvey, M.A.; Schilling, J.D.; Hultgren, S.J. Establishment of a persistent Escherichia coli reservoir during the acute phase of a bladder infection. Infect. Immun. 2001, 69, 4572-4579. [CrossRef] [PubMed]
48. Justice, S.S.; Hunstad, D.A.; Seed, P.C.; Hultgren, S.J. Filamentation by Escherichia coli subverts innate defenses during urinary tract infection. Proc. Natl. Acad. Soc. USA 2006, 103, 19884-19889. [CrossRef] [PubMed]
49. Rosen, D.A.; Hooton, T.M.; Stamm, W.E.; Humphrey, P.A.; Hultgren, S.J. Detection of intracellular bacterial communities in human urinary tract infection. PLoS Med. 2007, 4, e329. [CrossRef] [PubMed]
50. Robino, L.; Scavone, P.; Araujo, L.; Algorta, G.; Zunino, P.; Vignoli, R. Detection of intracellular bacterial communities in a child with Escherichia coli recurrent urinary tract infections. Pathog. Dis. 2013, 68, 78-81. [CrossRef] [PubMed]
51. Elliott, T.S.; Reed, L.; Slack, R.C.; Bishop, M.C. Bacteriology and ultrastructure of the bladder in patients with urinary tract infections. J. Infect. 1985, 11, 191-199. [CrossRef]
52. Lim, J.K.; Gunther, N.W.; Zhao, H.; Johnson, D.E.; Keay, S.K.; Mobley, H.L. In vivo phase variation of Escherichia coli type 1 fimbrial genes in women with urinary tract infection. Infect. Immun. 1998, 66, 3303-3310. [PubMed]
53. Hagan, E.C.; Lloyd, A.L.; Rasko, D.A.; Faerber, G.J.; Mobley, H.L. Escherichia coli global gene expression in urine from women with urinary tract infection. PLoS Pathog. 2010, 6, e1001187. [CrossRef] [PubMed]
54. Gunther, N.W.; Lockatell, V.; Johnson, D.E.; Mobley, H.L. In vivo dynamics of type 1 fimbria regulation in uropathogenic Escherichia coli during experimental urinary tract infection. Infect. Immun. 2001, 69, 2838-2846. [CrossRef] [PubMed]
55. Hultgren, S.J.; Porter, T.N.; Schaeffer, A.J.; Duncan, J.L. Role of type 1 pili and effects of phase variation on lower urinary tract infections produced by Escherichia coli. Infect. Immun. 1985, 50, 370-377. [PubMed]
56. Dodson, K.W.; Pinkner, J.S.; Rose, T.; Magnusson, G.; Hultgren, S.J.; Waksman, G. Structural basis of the interaction of the pyelonephritic E. coli adhesin to its human kidney receptor. Cell 2001, 105, 733-743. [CrossRef]
57. Guyer, D.M.; Radulovic, S.; Jones, F.E.; Mobley, H.L. Sat, the secreted autotransporter toxin of uropathogenic Escherichia coli, is a vacuolating cytotoxin for bladder and kidney epithelial cells. Infect. Immun. 2002, 70, 4539-4546. [CrossRef] [PubMed]
58. Mills, M.; Meysick, K.C.; O’Brien, A.D. Cytotoxic necrotizing factor type 1 of uropathogenic Escherichia coli kills cultured human uroepithelial 5637 cells by an apoptotic mechanism. Infect. Immun. 2000, 68, 5869-5880. [CrossRef] [PubMed]
59. Anderson, G.G.; Goller, C.C.; Justice, S.; Hultgren, S.J.; Seed, P.C. Polysaccharide capsule and sialic acid-mediated regulation promote biofilm-like intracellular bacterial communities during cystitis. Infect. Immun. 2010, 78, 963-975. [CrossRef] [PubMed]
60. Henderson, J.P.; Crowley, J.R.; Pinkner, J.S.; Walker, J.N.; Tsukayama, P.; Stamm, W.E.; Hooton, T.M.; Hultgren, S.J. Quantitative metabolomics reveals an epigenetic blueprint for iron acquisition in uropathogenic Escherichia coli. PLoS Pathog. 2009, 5, e1000305. [CrossRef] [PubMed]
61. Lane, M.C.; Mobley, H.L. Role of P-fimbrial-mediated adherence in pyelonephritis and persistence of uropathogenic Escherichia coli (UPEC) in the mammalian kidney. Kidney Int. 2007, 72, 19-25. [CrossRef] [PubMed]
62. Klumpp, D.J.; Rycyk, M.T.; Chen, M.C.; Thumbikat, P.; Sengupta, S.; Schaeffer, A.J. Uropathogenic Escherichia coli induces extrinsic and intrinsic cascades to initiate urothelial apoptosis. Infect. Immun. 2006, 74, 5106-5113. [CrossRef] [PubMed]
63. Thumbikat, P.; Berry, R.E.; Zhou, G.; Billips, B.; Yaggie, R.; Zaichuk, T.; Sun, T.; Schaeffer, A.J.; Klumpp, D.J. Bacteria-induced uroplakin signaling mediates bladder response to infection. PLoS Pathog. 2009, 5, e1000415. [CrossRef] [PubMed]
64. Hirose, T.; Kumamoto, Y.; Matsukawa, M.; Yokoo, A.; Satoh, T.; Matsuura, A. Study on local immune response in Escherichia coli-induced experimental urinary tract infection in mice—Infiltration of Ia-positive cells, macrophages, neutrophils, T cells and B cells. Jpn. Assoc. Infect. Dis. 1992, 66, 964-973.
65. Hopkins, W.J.; James, L.J.; Balish, E.; Uehling, D.T. Congenital immunodeficiencies in mice increase susceptibility to urinary tract infection. J. Urol. 1993, 149, 922-925. [PubMed]
66. Godaly, G.; Bergsten, G.; Frendeus, B.; Hang, L.; Hedlund, M.; Karpman, D.; Samuelsson, P.; Svensson, M.; Otto, G.; Wullt, B. et al. Innate defences and resistance to gram negative mucosal infection. Adv. Exp. Med. Biol. 2000, 485, 9-24. [PubMed]
67. Hannan, T.J.; Roberts, P.L.; Riehl, T.E.; van der Post, S.; Binkley, J.M.; Schwartz, D.J.; Miyoshi, H.; Mack, M.; Schwendener, R.A.; Hooton, T.M. et al. Inhibition of Cyclooxygenase-2 Prevents Chronic and Recurrent Cystitis. EBioMedicine 2014, 1, 46-57. [CrossRef] [PubMed]
68. Godaly, G.; Ambite, I.; Svanborg, C. Innate immunity and genetic determinants of urinary tract infection susceptibility. Curr. Opin. Infect. Dis. 2015, 28, 88-96. [CrossRef] [PubMed]
69. Chen, S.L.; Hung, C.S.; Pinkner, J.S.; Walker, J.N.; Cusumano, C.K.; Li, Z.; Bouckaert, J.; Gordon, J.I.; Hultgren, S.J. Positive selection identifies an in vivo role for FimH during urinary tract infection in addition to mannose binding. Proc. Natl. Acad. Soc. USA 2009, 106, 22439-22444. [CrossRef] [PubMed]
70. Le Trong, I.; Aprikian, P.; Kidd, B.A.; Forero-Shelton, M.; Tchesnokova, V.; Rajagopal, P.; Rodriguez, V.; Interlandi, G.; Klevit, R.; Vogel, V. et al. Structural basis for mechanical force regulation of the adhesin FimH via finger trap-like beta sheet twisting. Cell 2010, 141, 645-655. [CrossRef] [PubMed]
71. Aprikian, P.; Tchesnokova, V.; Kidd, B.; Yakovenko, O.; Yarov-Yarovoy, V.; Trinchina, E.; Vogel, V.; Thomas, W.; Sokurenko, E. Interdomain interaction in the FimH adhesin of Escherichia coli regulates the affinity to mannose. J. Biol. Chem. 2007, 282, 23437-23440. [CrossRef] [PubMed]
72. Aprikian, P.; Interlandi, G.; Kidd, B.; Le Trong, I.; Tchesnokova, V.; Yakovenko, O.; Whitfield, M.J.; Bullitt, E.; Stenkamp, R.E.; Thomas, W.; et al. The bacterial fimbrial tip acts as a mechnical force sensor. PLoS Biol. 2011, 9, e1000617. [CrossRef] [PubMed]
73. Schwartz, D.J.; Kalas, V.; Pinkner, J.S.; Chen, S.L.; Spaulding, C.N.; Dodson, K.W.; Hultgren, S.J. Positively selected FimH residues enhance virulence during urinary tract infection by altering FimH conformation. Proc. Natl. Acad. Soc. USA 2013, 110, 15530-15537. [CrossRef] [PubMed]
74. Schwartz, D.J.; Conover, M.S.; Hannan, T.J.; Hultgren, S.J. Uropathogenic Escherichia coli superinfection enhances the severity of mouse bladder infection. PLoS Pathog. 2015, 11, e1004599. [CrossRef] [PubMed]
75. Sokurenko, E.V.; Vogel, V.; Thomas, W.E. Catch-bond mechanism of force-enhanced adhesion: Counterintuitive, elusive, but… widespread? Cell Host Microbe 2008, 4, 314-323. [CrossRef] [PubMed
76. Rodriquez, V.B.; Kidd, B.A.; Interlandi, G.; Tchesnokova, V.; Sokurenko, E.; Thomas, W.E. Allosteric coupling in the bacteial adhesive protein FimH. J. Biol. Chem. 2013, 288, 24128-24139. [CrossRef] [PubMed]
77. Schaeffer, A.J.; Schwan, W.R.; Hultgren, S.J.; Duncan, J.L. Relationship of type 1 pilus expression in Escherichia coli to ascending urinary tract infections in mice. Infect. Immun. 1987, 55, 373-380. [PubMed]
78. O’Hanley, P.; Low, D.; Romero, I.; Lark, D.; Vosti, K.; Falkow, S.; Scholnik, G. Gal-Gal binding and hemolysin phenotypes and genotypes associated with uropathogenic Escherichia coli. N. Engl. J. Med. 1985, 313, 414-420. [CrossRef] [PubMed]
79. Wullt, B.; Bergsten, G.; Connell, H.; Rullano, P.; Gebretsadik, N.; Hull, R.; Svanborg, C. P fimbriae enhance the early establishment of Escherichia coli in the human urinary tract. Mol. Microbiol. 2000, 38, 456-464. [CrossRef] [PubMed]
80. Zhang, J.P.; Normark, S. Induction of gene expression in Escherichia coli after pilus-mediated adherence. Science 1996, 273, 1234-1236. [CrossRef] [PubMed]
81. Lund, B.; Lindberg, F.; Marklund, B.I.; Normark, S. The PapG protein is the alpha-D-galactopyranosyl-(1-4)-beta-D-galactopyranose-binding adhesin of uropathogenic Escherichia coli. Proc. Natl. Acad. Soc. USA 1987, 84, 5898-5902. [CrossRef]
82. Lanne, B.; Olsson, B.M.; Jovall, P.A.; Angstrum, J.; Linder, H.; Marklund, B.I.; Bergstrum, J.; Karlsson, K.A. Glycoconjugate receptors for P-fimbriated Escherichia coli in the mouse. An animal model of urinary tract infection. J. Biol. Chem. 1995, 270, 9017-9025. [CrossRef] [PubMed]
83. Haslam, D.B.; Baenziger, J.U. Expression cloning of Forssman glycolipid synthetase: A novel member of the histo-blood group ABO gene family. Proc. Natl. Acad. Soc. USA 1996, 93, 10697-106702. [CrossRef]
84. Breimer, M.E.; Karlsson, K.A. Chemical and immunological identification of glycolipid-based blood group ABH and Lewis antigens in human kidney. Biochim. Biophys. Acta 1983, 75, 170-177. [CrossRef]
85. Breimer, M.E.; Hansson, G.C.; Leffler, H. The specific glycosphingolipid composition of human ureteral epithelial cells. J. Biochem. 1985, 98, 1169-1180. [PubMed]
86. Nuccio, S.; Baumler, A.J. Evolution of the chaperone/usher assembly pathway: Fimbrial classification goes Greek. Microbiol. Mol. Biol. Rev. 2007, 71, 551-575. [CrossRef] [PubMed]
87. Wurpel, D.J.; Beatson, S.A.; Totsika, M.; Petty, N.K.; Schembri, M.A. Chaperone-usher fimbriae of Escherichia coli. PLoS ONE 2013, 8, e52835. [CrossRef] [PubMed]
88. Lillington, J.; Geibel, S.; Waksman, G. Biogenesis and adhesion of type 1 and P pili. Biochim. Biophys. Acta 2014, 1840, 2783-2793. [CrossRef] [PubMed]
89. Parkkinen, J.; Rogers, G.N.; Korhonen, T.; Dahr, W.; Finne, J. Identification of the O-linked sialyloligosaccharides of glycophorin A as the erythrocyte receptors for S-fimbriated Escherichia coli. Infect. Immun. 1986, 54, 37-42. [PubMed]
90. Nowicki, B.; Selvarangan, R.; Nowicki, S. Family of Escherichia coli Dr adhesins: Decay-accelerating factor receptor recognition and invasiveness. J. Infect. Dis. 2001, 183, 24-27. [CrossRef] [PubMed]
91. Goluszko, P.; Popov, V.; Selvarangan, R.; Nowicki, S.; Pham, T.; Nowicki, B.J. Dr fimbriae operon of uropathogenic Escherichia coli mediate microtubule-dependent invasion to the HeLa epithelial cell line. J. Infect. Dise. 1997, 176, 158-167. [CrossRef]
92. Spurbeck, R.R.; Stapleton, A.E.; Johnson, J.R.; Walk, S.T.; Hooton, T.M.; Mobley, H.L. Fimbrial Profiles Predict Virulence of Uropathogenic E. coli Strains: Contribution of Ygi and Yad Fimbriae. Infect. Immun. 2011, 79, 4753-4763. [CrossRef] [PubMed]
93. Wurpel, D.J.; Totsika, M.; Allsopp, L.P.; Hartley-Tassell, L.E.; Day, C.J.; Peters, K.M.; Sarkar, S.; Ulett, G.C.; Yang, J.; Tiralongo, J.; et al. F9 fimbriae of uropathogenic Escherichia coli are expressed at low temperature and recognise Galbeta1-3GlcNAc-containing glycans. PLos ONE 2014, 9, e93177.
94. Buckles, E.L.; Bahrani-Mougeot, F.K.; Molina, A.; Lockatell, C.V.; Johnson, D.E.; Drachenberg, C.B.; Burland, V.; Blattner, F.R.; Donnenberg, M.S. Identification and characterization of a novel uropathogenic Escherichia coli-associated fimbrial gene cluster. Infect. Immun. 2004, 72, 3890-3901. [CrossRef] [PubMed]
95. Carey, A.J.; Tan, C.K.; Ipe, D.S.; Sullivan, M.J.; Cripps, A.W.; Schembri, M.A.; Ulett, G.C. Urinary tract infection of mice to model human disease: practicalities, implications and limitations. Crit. Rev. Microbiol. 2015. [CrossRef] [PubMed]
96. Mabeck, C.E. Treatment of uncomplicated urinary tract infection in non-pregnant women. Postgrad. Med. J. 1972, 48, 69-75. [CrossRef] [PubMed]
97. Ferry, S.; Holm, S.; Stenlund, H.; Lundholm, R.; Monsen, T. The natural course of uncomplicated lower urinary tract infection in women illustrated by a randomized placebo controlled study. Scand. J. Infect. Dis. 2004, 36, 296-301. [CrossRef] [PubMed]
98. Hannan, T.J.; Mysorekar, I.U.; Hung, C.S.; Isaacson-Schmid, M.L.; Hultgren, S.J. Early severe inflammatory responses to uropathogenic E. coli predispose to chronic and recurrent urinary tract infection. PLoS Pathog. 2010, 6, e1001042. [CrossRef] [PubMed]
99. Mysorekar, I.U.; Hultgren, S.J. Mechanisms of uropathogenic Escherichia coli persistence and eradication from the urinary tract. Proc. Natl. Acad. Soc. USA 2006, 103, 14170-14175. [CrossRef] [PubMed]
100. Schilling, J.D.; Hultgren, S.J. Recent advances into the pathogenesis of recurrent urinary tract infections: The bladder as a reservoir for uropathogenic Escherichia coli. Int. J. Antimicrob. Agents 2002, 19, 457-460. [CrossRef]
101. Schlager, T.A.; LeGallo, R.; Innes, D.; Hendley, J.O.; Peters, C.A. B cell infiltration and lymphonodular hyperplasia in bladder submucosa of patients with persistent bacteriuria and recurrent urinary tract infections. J. Urol. 2011, 186, 2359-2364. [CrossRef]
102. Hansson, S.; Hanson, E.; Hjalmas, K.; Hultengren, M.; Jodal, U.; Olling, S.; Svanborg-Eden, C. Follicular cystitis in girls with untreated asymptomatic or covert bacteriuria. J. Urol. 1990, 143, 330-332. [PubMed]
103. Bleidorn, J.; Gagyor, I.; Kochen, M.M.; Wegscheider, K.; Hummers-Pradier, E. Symptomatic treatment (ibuprofen) or antibiotics (ciprofloxacin) for uncomplicated urinary tract inections? Results of a randomized contolled pilot trial. BMC Med. 2010, 8, 30. [CrossRef] [PubMed]
104. Gagyor, I.; Bleidorn, J.; Kochen, M.M.; Schmiemann, G.; Wegscheider, K.; Hummers-Pradier, E. Ibuprofen versus fosfomycin for uncomplicated urinary tract infection in women: randomised controlled trial. Br. Med. J. 2015, 351, h6544.
105. Ragnarsdottir, B.; Lutay, N.; Gronberg-Hernandez, J.; Koves, B.; Svanborg, C. Genetics of innate immunity and UTI susceptibility. Nat. Rev. Urol. 2011, 8, 449-468. [CrossRef] [PubMed]
106. Arias, C.A.; Murray, B.E. The rise of the Enterococcus: Beyond vancomycin resistance. Nat. Rev. Microbiol. 2012, 10, 266-278. [CrossRef] [PubMed]
107. Guiton, P.S.; Hung, C.S.; Hancock, L.; Caparon, M.G.; Hultgren, S.J. Enterococcal biofilm formation and virulence in an optimized murine model of foreign body-associated urinary tract infections. Infect. Immun. 2010, 78, 4166-4175. [CrossRef] [PubMed]
108. Nielsen, H.V.; Guiton, P.S.; Kline, K.A.; Port, G.C.; Pinkner, J.S.; Neiers, F.; Normark, S.; Henriques-Normark, B.; Caparon, M.G.; Hultgren, S.J. The metal ion-dependent adhesion site motif of the Enterococcus faecalis EbpA pilin mediates pilus function in catheter-associated urinary tract infection. mBio 2012. [CrossRef] [PubMed]
109. Flores-Mireles, A.L.; Pinkner, J.S.; Caparon, M.G.; Hultgren, S.J. EbpA vaccine antibodies block binding of Enterococcus faecalis to fibrinogen to prevent catheter-associated bladder infection in mice. Sci. Transl. Med. 2014. [CrossRef] [PubMed]
110. Singh, K.V.; Nallapareddy, S.R.; Murray, B.E. Importance of the ebp (endocarditis- and biofilm-associated pilus) locus in the pathogenesis of Enteroccous faecalis ascending urinary tract infection. J. Infect. Dis. 2007, 195, 1671-1677. [CrossRef] [PubMed]
111. Goble, N.M.; Clarke, T.; Hammonds, J.C. Histological changes in the urinary bladder secondary to urethral catheterisation. Br. J. Urol. 1989, 63, 354-357. [CrossRef] [PubMed]
112. Glahn, B.E.; Braendstrup, O.; Olesen, H.P. Influence of drainage conditions on mucosal bladder damage by indwelling catheters. II. Histological study. Scand. J. Urol. Nephrol. 1988, 22, 93-99. [PubMed]
113. Peychl, L.; Zalud, R. Changes in the urinary bladder caused by short-term permanent catheter insertion. Cas. Lek. Cesk. 2008, 147, 325-329. [PubMed]
114. Flores-Mireles, A.L.; Walker, J.N.; Bauman, T.M.; Potretzke, A.M.; Schreiber, H.L.; Park, A.M.; Pinkner, J.S.; Caparon, M.G.; Hultgren, S.J.; Desai, A. Fibrinogen release and deposition on urinary catheters placed during urologic procedures. J. Urol. 2016. [CrossRef] [PubMed]
115. Rivera, J.; Vannakambadi, G.; Hook, M.; Speziale, P. Fibrinogen-binding proteins of Gram-positive bacteria. Thromb Haemostasis. 2007, 98, 503-511. [CrossRef]
116. Guiton, P.S.; Cusumano, C.K.; Kline, K.A.; Dodson, K.W.; Han, Z.; Janetka, J.W.; Henderson, J.P.; Caparon, M.G.; Hultgren, S.J. Combinatorial small-molecule therapy prevents uropathogenic Escherichia coli catheter-associated urinary tract infections in mice. Antimicrob. Agents Chemother. 2012, 56, 4738-4745. [CrossRef] [PubMed]
117. Alteri, C.J.; Hagan, E.C.; Sivick, K.E.; Smith, S.N.; Mobley, H.L. Mucosal immunization with iron receptor antigens protects against urinary tract infection. PLoS Pathog. 2009, 5, e1000586. [CrossRef] [PubMed]
118. Roberts, J.A.; Kaack, M.B.; Baskin, G.; Chapman, M.R.; Hunstad, D.A.; Pinkner, J.S.; Hultgren, S.J. Antibody responses and protection from pyelonephritis following vaccination with purified Escherichia coli PapDG protein. J. Urol. 2004, 171, 1682-1685. [CrossRef] [PubMed]
119. Billips, B.K.; Yaggie, R.E.; Cashy, J.P.; Schaeffer, A.J.; Klumpp, D.J. A live-attenuated vaccine for the treatment of urinary tract infection by uropathogenic Escherichia coli. J. Infect. Dis. 2009, 200, 263-272. [CrossRef] [PubMed]
120. Langermann, S.; Palaszynski, S.; Barnhart, M.; Auguste, G.; Pinkner, J.S.; Burlein, J.; Barren, P.; Koenig, S.; Leath, S.; Jones, C.H. et al. Prevention of Mucosal Escherichia coli Infection by FimH-Adhesin-Based Systemic Vaccination. Science 1997, 276, 607-611. [CrossRef] [PubMed]
121. Langermann, S.; Mollby, R.; Burlein, J.E.; Palaszynski, S.R.; Auguste, C.G.; DeFusco, A.; Strouse, R.; Schenerman, M.A.; Hultgren, S.J.; Pinkner, J.S. et al. Vaccination with FimH adhesin protects cynomolgus monkeys from colonization and infection by uropathogenic Escherichia coli. J Infect. Dis. 2000, 181, 774-778. [CrossRef] [PubMed]
122. Roberts, J.A.; Hardaway, K.; Kaack, B.; Fussell, E.N.; Baskin, G. Prevention of pyelonephritis by immunizaiton with P-fimbriae. J. Urol. 1984, 131, 602-607. [PubMed]
123. Goluszko, P.; Goluszko, E.; Nowicki, B.; Nowicki, S.; Popov, V.; Wang, H.Q. Vaccination with purified Dr. Fimbriae reduces mortality associated with chronic urinary tract infection due to Escherichia coli bearing Dr. adhesin. Infect Immun. 2005, 73, 627-631. [CrossRef] [PubMed]
124. Kranjcec, B.; Papes, D.; Altarac, S. D-mannose powder for prophylaxis of recurrent urinary tract infections in women: a randomized clinical trial. World J. Urol. 2014, 32, 79-84. [CrossRef] [PubMed]
125. Han, Z.; Pinkner, J.S.; Ford, B.; Obermann, R.; Nolan, W.; Wildman, S.A.; Hobbs, D.; Ellenberger, T.; Cusumano, C.K.; Hultgren, S.J. et al. Structure-based drug design and optimization of mannoside bacterial FimH antagonists. J. Med. Chem. 2010, 53, 4779-4792. [CrossRef] [PubMed]
126. Kleeb, S.; Pang, L.; Mayer, K.; Eris, D.; Sigl, A.; Preston, R.C.; Zihlmann, P.; Sharpe, T.; Jakob, R.P.; Abgottspon, D. et al. FimH antagonists: bioisosteres to improve the in vitro and in vivo PK/PD profile. J. Med. Chem. 2015, 58, 2221-2239.
127. Cusumano, C.K.; Pinkner, J.S.; Han, Z.; Greene, S.A.; Ford, B.A.; Crowley, J.R.; Henderson, J.P.; Janetka, J.W.; Hultgren, S.J. Treatment and prevention of urinary tract infection with orally active FimH inhibitors. Sci. Transl. Med. 2011, 3, 109-115. [CrossRef] [PubMed]
128. Totsika, M.; Kostakioti, M.; Hannan, T.J.; Upton, M.; Beatson, S.A.; Janetka, J.W.; Hultgren, S.J.; Schembri, M.A. A FimH inhibitor prevents acute bladder infection and treats chronic cystitis caused by multidrug-resistant uropathogenic Escherichia coli ST131. J. Infect. Dis. 2013, 208, 921-928. [CrossRef] [PubMed]
129. Klein, T.; Abgottspon, D.; Wittwer, M.; Rabbani, S.; Herold, J.; Jiang, X.; Kleeb, S.; Luthi, C.; Scharenberg, M.; Bezenuon, J. et al. FimH antagonists for the oral treatment of urinary tract infections: From design and synthesis to in vitro and in vivo evaluation. J. Med. Chem. 2010, 53, 8627-8641. [CrossRef] [PubMed]
130. Bouckaert, J.; Berglund, J.; Schembri, M.; De Genst, E.; Cools, L.; Wuhrer, M.; Hung, C.S.; Pinkner, J.; Slattegard, R.; Zavialov, A. et al. Receptor binding studies disclose a novel class of high-affinity inhibitors of the Escherichia coli FimH adhesin. Mol. Microbiol. 2005, 55, 441-455. [CrossRef] [PubMed]
131. Aberg, V.; Almqvist, F. Pilicides-small molecules targeting bacterial virulence. Org. Biomol. Chem. 2007, 5, 1827-1834. [CrossRef] [PubMed]
132. Aberg, V.; Fallman, E.; Axner, O.; Uhlin, B.E.; Hultgren, S.J.; Almqvist, F. Pilicides regulate pili expression in E. coli without affecting the functional properties of the pilus rod. Mol. bioSyst. 2007, 3, 214-218. [CrossRef] [PubMed]
133. Pinkner, J.S.; Remaut, H.; Buelens, F.; Miller, E.; Aberg, V.; Pemberton, N.; Hedenstrom, M.; Larsson, A.; Seed, P.; Waksman, G. et al. Rationally designed small compounds inhibit pilus biogenesis in uropathogenic bacteria. Proc. Natl. Acad. Soc. USA 2006, 103, 17897-17902. [CrossRef] [PubMed]
134. Piatek, R.; Zalewska-Piatek, B.; Dzierzbicka, K.; Makowiec, S.; Pilipczuk, J.; Szemiako, K.; Cyranka-Czaja, A.; Wojciechowski, M. Pilicides inhibit the FGL chaperone/usher assisted biogenesis of the Dr fimbrial polyadhesin from uropathogenic Escherichia coli. BMC Microbiol. 2013. [CrossRef] [PubMed]
135. Greene, S.E.; Pinkner, J.S.; Chorell, E.; Dodson, K.W.; Shaffer, C.L.; Conover, M.S.; Livny, J.; Hadjifrangiskou, M.; Almqvist, F.; Hultgren, S.J. Pilicide ec240 disrupts virulence circuits in uropathogenic Escherichia coli. mBio 2014, 5, e02038. [CrossRef] [PubMed]